Severe acne: analysis of some modern methods of treatment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article provides an updated review of the data on severe acne and the treatment of this dermatosis using systemic isotretinoin. The mechanisms of action, starting and course doses, as well as issues of bioavailability of isotretinoin are discussed. The analysis of information about isotretinoin, manufactured by Lidose technology, is presented.

Full Text

Restricted Access

About the authors

E. R Araviyskaya

FSBEI HE First Saint-Petersburg State Medical University n.a. Acad. I.P. Pavlov of RMH

Email: arelenar@mail.ru
MD, Professor at the Department of Dermatology with Clinic

References

  1. Leyden J. A review of the use of combination therapies for the treatment of acne vulgaris. J. Am. Acad. Dermatol. 2003;49:200-10.
  2. Nast A., Dreno B., Bettoli V., Bukvic Mokos Z., Degitz K., Dressier C., Finlay A.Y., Haedersdal M., Lambert J., Layton A., Lomholt H.B., Lopez-Estebaranz J.L., Ochsendorf F., Oprica C., Rosumeck S., Simonart T., Werner R.N., Gollnick H. European Evidence-based (S3) Guidelines for the Treatment of Acne. J. Eur. Acad. Dermatol. Venenreol. 2016;30(8):1261-68.
  3. Poli F., Dreno B., Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J. Eur. Acad. Dermatol. Venereol. 200;15(6):541-45.
  4. Amado J.M., Matos M.E., Abreu A.M., Loureiro L., Oliveira J, Verde A., Massa A. The prevalence of acne in the north of Portugal. J. Eur. Acad. Dermatol. Venereol. 2006;20:1287-95.
  5. Nijsten T., Rombouts S., Lambert J. Acne is prevalent but use of its treatments is infrequent among adolescents from the general population. J. Eur. Acad. Dermatol. Venereol. 2007; 21:163-68.
  6. Smithard A., Glazebrook C., Williams H.C. Acne prevalence, knowledge about acne and psychological morbidity in mid-adolescence: a community-based study. Br. J. Dermatol. 2001;145(2): 274-79.
  7. Mallon E., Newton J.N., Klassen A., StewartBrown S.L., Ryan T.J., Finlay A.Y. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br. J. Dermatol. 1999;140(4):672-76.
  8. Tan J.K. Psychosocial impact of acne vulgaris: evaluating the evidence. Skin Therapy Lett. 2004;9(7):1-3, 9.
  9. Dreno B., Poli F. Epidemiology of acne. Dermatology. 2003;206(1):7-10.
  10. Herane M.I., Ando I. Acne in infancy and acne genetics. Dermatology. 2003;206(1):24-8.
  11. Кубанова А.А., Аравийская Е.Р., Соколовский Е.В., Дворова Е.К., Фадеева Е.И. Системное лечение тяжелых форм акне: опыт использования изотретиноина в Российской Федерации. Вестн. дерматол. и венерол. 2013;5:102-14.
  12. Perkins A., Cheng C.E., Hillebrand G.G., Miyamoto K., Kimball A.B. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. J. Eur. Acad. Dermatol. Venereol. 2010;25(9):1054-60.
  13. Smith R.N., Mann N.J., Braue A., Mäkeläinen H., Varigos G.A. A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. Am. J. Clin. Nutr. 2007;86(1):107-15.
  14. Федеральные клинические рекомендации по ведению больных акне. М., 2013. 20 с.
  15. Peck G.L., Olsen T.G., Butkus D., Pandya M., Arnaud-Battandier J., Gross E.G., Windhorst D.B., Cheripko J. Isotretinoin versus placebo in the treatment of cystic acne. A randomized doubleblind study. J. Am. Acad. Dermatol. 1982;6(Pt. 4, Suppl. 2):735-45.
  16. Pigatto P.D., Finzi A.F., Altomare G.F., Polenghi M.M., Vergani C., Vigotti G. Isotretinoin versus minocycline in cystic acne: a study of lipid metabolism. Dermatologica. 1986; 172(3):154-59.
  17. Lester R.S., Schachter G.D., Light M.J. Isotretinoin and tetracycline in the management of severe nodulocystic acne. Int. J. Dermatol. 1985;24(4):252-57.
  18. Gollnick H.P., Graupe K., Zaumseil R.P. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 2001; 11(6): 538-544.
  19. Oprica C., Emtestam L., Hagströmer L., Nord C.E. Clinical and microbiological comparisons of isotretinoin vs. tetracycline in acne vulgaris. Acta. Derm. Venereol. 2007;87(3):246-54.
  20. Dhir R., Gehi N.P., Agarwal R., More Y.E. Oral isotretinoin is as effective as a combination of oral isotretinoin and topical anti-acne agents in nodulocystic acne. Indian J. Dermatol. Venereol. Leprol. 2008;74(2):187.
  21. Karlsson T., Vahlquist A., Kedishvili N., Törmä H. 13-cis-retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands? Biochem. Biophys. Res. Comm. 2003;303(1):273-78.
  22. Dispenza M., Wolpert E.B., Gilliland K.L., Dai J.P., Cong Z., Nelson A.M., Thiboutot D.M. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J. Invest. Dermatol. 2012;132(9):2198-205.
  23. Papaconstantinou E., Aletras A.J., Glass E., Tsogas P., Dionyssopoulos A., Adjaye J., Fimmel S., Gouvousis P., Herwig R., Lehrach H., Zouboulis C.C., Karakiulakis G. Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J. Invest. Dermatol. 2005;125(4):673-84.
  24. Lee J.W., Yoo K.H., Park K.Y., Han T.Y., Li K., Seo S.J., Hong C.K. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br. J. Dermatol. 2011;164; 369-75.
  25. Cyrulnik A.A., Viola K.V., Gewirtzman A.J., Cohen S.R. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int. J. Dermatol. 2012;51;1123-30.
  26. Goldsmith L.A., Bolognia J.L., Callen J.P., et al. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J. Am. Acad. Dermatol. 2004;50:900-906.
  27. Zaenglein A.L., Pathy A.L., Schlosser B.J., et al. Guidelines of care for the management of acne vulgaris. J. Am. Acad. Dermatol. 2016;74(5):945-73.
  28. Blasiak R.C., Stamey C.R., Burkhart C.N., et al. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA. Dermatol. 2013;149:1392-98.
  29. Mandekou-Lefaki S., Delli F., Teknetzis A., Euthimiadou R., Karakatsanis G. Low-dose schema of isotretinoin in acne vulgaris. J. Int. Clin. Pharmacol. Res. 2003;23:41-6.
  30. Nau H. Teratogenicity of isotretinoin revisited: species variation and the role of all-transretinoic acid. J. Am. Acad. Dermatol. 2001; 45(5):183-87.
  31. Lee H.E., Chang S.K., Lee Y., Kim C.D., Seo Y.J.,Lee J.H., Im M. Effect of antihistamine as an adjuvant treatment of isotretinoin in acne: a randomized, controlled comparative study. J. Eur. Acad. Dermatol. Venereol. 2014;28(12):1654-60.
  32. Stewart M.E., Benoit A.M., Downing D.T., Strauss J.S. Suppression of sebum secretion with 13-cis-retinoic acid: effect on individual skin surface lipids and implications for their anatomic origin. J. Invest. Dermatol. 1984;82:74-8.
  33. King R., Jones D.H., Daltrey D.C., Cunliffe W.J. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Brit. J. Dermatol. 1982;107:583-90.
  34. Jeremy A., Holland D.B., Roberts S.G., Thomson K.F, Cunliffe WJ. Inflammatory events are involved in acne lesions initiation J. Invest. Dermatol. 2003;121: 20-7.
  35. Araviiskaia E., Dréno B. The role of topical dermocosmetics in acne vulgaris. J. Eur. Acad. Dermatol. Venereol. 2016;30(6):926-35.
  36. Colburn W.A., Gibson D.M., Wiens R.E., Hanigan J.J. Food increases the bioavailability of isotretinoin. J Clin Pharmacol. 1983;23(11-12):534-39.
  37. Tan J., Knezevic S. Improving Bioavailability with a Novel Isotretinoin Formulation (Isotretinoin-Lidose). Skin Therapy letter. 2013;18(6).
  38. HLR Technology Corporation (Hoffman-La Roche), Nutley, NJ. NDA 21-177: New formulation isotretinoin [Executive Summary]. Summary date: August 9, 2000. Available at: www.fda.gov/ohrms/dockets/ac/00/ backgrd/3639b1d_01. doc. Accessed July 29, 2013.
  39. Webster G.F., Leyden J.J., Gross J.A. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study. J. Am. Acad. Dermatol. 2013. [Epub ahead of print].
  40. Волкова Е.Н., Есимбиева М.Л., Ландышева К.А., Лебедева С.В., Елистратова И.В. Инновация ведения больных с акне: предварительные результаты лечения. Клин. дерматол. и венерол. 2011;1:59-63.
  41. Самцов А.В., Стаценко А.В., Волкова С.В., Горбунов Ю.Г., Хайрутдинов В.Р Вопросы эффективности и безопасности применения акнекутана в терапии акне. Вестн. дерматол. и венерол. 2011;2:58-62.
  42. Сафонова Т.Г., Владимиров В.В., Сирмайс Н.С. Системные ретиноиды в терапии тяжелых и резистентных форм акне. Клин. дерматол. и венерол. 2013;3:60-2.
  43. Кунгуров Н.Н., Кохан М.М., Шабардина О.В. Опыт терапии больных среднетяжелыми и тяжелыми акне препаратом изотретиноин. Вестн. дерматол. и венерол. 2013;1:56-62.
  44. Масюкова С.А., Мордовцева В.В., Кахишвили Н.Н. Лечение акне низкими дозами изотретиноина. Клин дерматол. и венерол. 2012;2:79-85.
  45. Сергеева И.Г., Криницына Ю.М., Онипченко В.В., Гвоздарева М.А., Дягилева А.А. Клинико-морфологическая характеристика состояния кожи пациентов с акне в динамике терапии изотретиноином в форме LIDOSE. Вестн. дерматол. и венерол. 2012;5:120-26.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies